Form 4: Apyx Medical Corp Director John C. Andres Acquires 17,000 Stock Options

Director John C. Andres acquired 17,000 stock options in Apyx Medical Corp on August 8, 2024, as part of the Director Compensation Program.

Summary

• On August 8, 2024, John C. Andres, a director of Apyx Medical Corp, acquired 17,000 stock options.
• The exercise price of these options is $1.02.
• The options were issued as part of the Issuer's Director Compensation Program.
• The options vest ratably over a 12-month period and become fully vested and exercisable on the first anniversary of the grant date.
• The expiration date for these options is August 8, 2034.

Sentiment

Score: 7

Explanation: The document indicates a standard compensation practice, suggesting stability and alignment of interests. The sentiment is neutral to positive.

Positives

• The grant of stock options to directors aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The director's holdings will increase as the options vest over the next 12 months.

Industry Context

Granting stock options to directors is a common practice to align their interests with shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Director compensation packages vary widely across the medical device industry.
• Stock options are a standard component of compensation for directors in publicly traded companies, similar to companies like Medtronic and Stryker.
• The vesting schedule of 12 months is fairly standard.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with theirs.
• Employees are not directly impacted by this transaction.

Key Dates